Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
/CNW/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and...
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
Regulatory News:
Why These Two Biotech Stocks Blasted Higher This Week
There's nothing like a big-premium buyout to send a company's share price to the moon.
SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc....
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
The market is moving higher, and these small companies are helping.
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Regulatory News:
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
Regulatory News: